Ajanta Pharma Soars 5% on Biocon Weight-Loss Drug Marketing Deal

• Ajanta Pharma shares surged 5% to a five-month high after signing an in-licensing pact with Biocon for the weight-loss drug Semaglutide.
• Biocon will supply Semaglutide to Ajanta Pharma for exclusive marketing in 23 countries and semi-exclusive in 3 countries across Africa, West Asia, and Central Asia.
• Semaglutide, a GLP-1 receptor agonist, aims to improve glycemic control in adults, with regulatory approvals expected in late 2026 or early 2027.
• Ajanta Pharma's MD, Yogesh Agrawal, highlighted the potential of GLP-1 therapies and Ajanta's strong market presence to build Semaglutide into a high-growth brand.
• Biocon's CEO, Siddharth Mittal, emphasized the partnership's role in expanding Biocon's GLP-1 portfolio and providing affordable access to Semaglutide.

Why It Matters: Ajanta Pharma's strategic pact with Biocon for Semaglutide marketing boosts shares and global reach.